'Maraviroc' presentation slideshows

Efficacy and Safety of Maraviroc in Antiretroviral-Experienced Patients Infected With CCR5-Tropic HIV-1: 48-Week Results

314 views • 16 slides

April 2008, Belfast

BHIVA 14th Annual Conference. April 2008, Belfast. Belfast Waterfront Hall. BHIVA 14th Annual Conference. 500 delegates 200 Poster presentations 30 oral abstracts 10 Satellite symposiums 5 Plenary sessions 3 big workshops

278 views • 15 slides

Andre J Marozsan Progenics Pharmaceuticals, Inc.

CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist. Andre J Marozsan Progenics Pharmaceuticals, Inc. PRO 140 Background. Humanized CCR5 monoclonal antibody Broadly and potently inhibits CCR5-mediated HIV-1 entry in vitro

378 views • 13 slides

VIRTUAL MEDZONE

VIRTUAL MEDZONE. Your Resource for HIV Related Innovative Medical Communication. HIV CASE PRESENTATIONS. David Fletcher MD FRCPC. CASE 1 Follow-up. Proviral DNA tropism testing revealed non-R5 virus hence Maraviroc was not a viable option . CASE 1 Follow-up.

128 views • 5 slides